19208-Lung Cancer-NA-1519

Lung Cancer

A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)

  • Details

ClinicalTrials.gov ID: NCT04222972
Diagnosis Type: NA
USOR Number: 19208

  • Address

1105 Central Expressway, Suite 320
Allen, TX 75013
P: (469) 467-4392

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.